{
    "organizations": [],
    "uuid": "a25a37c3ac24853259176c7ddb2e8511c71e0eb1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-carna-biosciences-and-sumitomo-dai/brief-carna-biosciences-and-sumitomo-dainippon-pharma-sign-agreement-on-joint-research-development-and-commercialization-of-kinase-inhibitors-idUSL3N1R939H",
    "ord_in_thread": 0,
    "title": "BRIEF-Carna Biosciences and Sumitomo Dainippon Pharma sign agreement on joint research, development, and commercialization of kinase inhibitors",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - Carna Biosciences Inc\n* Says it and Sumitomo Dainippon Pharma Co Ltd , signed an agreement on joint research with the aim of discovering novel kinase inhibitors for psychiatric and neurological disorders, as well as on the subsequent development and commercialization of such therapeutic agent\nSource text in Japanese: goo.gl/UpXnjP\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-03-27T15:48:00.000+03:00",
    "crawled": "2018-03-28T18:45:00.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "carna",
        "bioscience",
        "inc",
        "say",
        "sumitomo",
        "dainippon",
        "pharma",
        "co",
        "ltd",
        "signed",
        "agreement",
        "joint",
        "research",
        "aim",
        "discovering",
        "novel",
        "kinase",
        "inhibitor",
        "psychiatric",
        "neurological",
        "disorder",
        "well",
        "subsequent",
        "development",
        "commercialization",
        "therapeutic",
        "agent",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}